Zanubrutinib is Well Tolerated and Effective in Acalabrutinib-Intolerant Patients with B-cell Malignancies

被引：0
|
作者：
Shadman, Mazyar [1 ,2 ]
Flinn, Ian W. [3 ]
Levy, Moshe Y. [4 ]
Freeman, Benjamin B. [5 ]
Zhang, Ben [6 ]
Burke, John M. [7 ]
Cultrera, Jennifer L. [8 ]
Yimer, Habte A. [9 ]
Kingsley, Edwin C. [10 ]
Farber, Charles M. [11 ]
D'Olimpio, James [12 ]
Yao, Hui [13 ]
Idoine, Adam [14 ]
An, Qi [13 ]
Sharman, Jeff P. [15 ]
机构：
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA USA
[2] Univ Washington, Seattle, WA USA
[3] Tennessee Oncol, OneOncol, Nashville, TN USA
[4] Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA
[5] Summit Med Grp, Florham Pk, NJ USA
[6] Minnesota Oncol Clin, Burnsville, MN USA
[7] US Oncol Res, Rocky Mt Canc Ctr, Aurora, CO USA
[8] Florida Canc Specialists & Res Inst, Leesburg, FL USA
[9] US Oncol Res, Texas Oncol Tyler, Tyler, TX USA
[10] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[11] Morristown Med Ctr, Atlantic Hematol Oncol, Morristown, NJ USA
[12] Clin Res Alliance, Westbury, NY USA
[13] BeiGene Shanghai Co Ltd, Shanghai, Peoples R China
[14] BeiGene USA Inc, San Mateo, CA USA
[15] US Oncol Res, Willamette Valley Canc Inst & Res Ctr, Eugene, OR USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-198250
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4632 / 4633
页数：2
相关论文
共 50 条
  • [31] Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies (vol 6, pg 1296, 2022)
    Tam, C. S.
    Dimopoulos, M.
    Garcia-Sanz, R.
    BLOOD ADVANCES, 2022, 6 (17) : 4983 - 4983
  • [32] Assessment of ethnic differences in pharmacokinetics and clinical responses of acalabrutinib between Chinese and White patients with B-cell malignancies
    Yao, Tingting
    Ding, Junjie
    Sharma, Shringi
    Li, Yunfei
    Xu, Qianwei
    Ma, Peiming
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2025,
  • [33] Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell Malignancies
    Edlund, Helena
    Lee, Sun Ku
    Andrew, Marilee A.
    Slatter, J. Greg
    Aksenov, Sergey
    Al-Huniti, Nidal
    CLINICAL PHARMACOKINETICS, 2019, 58 (05) : 659 - 672
  • [34] Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell Malignancies
    Helena Edlund
    Sun Ku Lee
    Marilee A. Andrew
    J. Greg Slatter
    Sergey Aksenov
    Nidal Al-Huniti
    Clinical Pharmacokinetics, 2019, 58 : 659 - 672
  • [35] Pirtobrutinib monotherapy in patients with relapsed/refractory B-cell malignancies intolerant to prior covalent BTK inhibitor
    Munir, Talha
    Shah, Nirav N.
    Wang, Michael
    Brown, Jennifer R.
    Patel, Krish
    Woyach, Jennifer
    Wierda, William G.
    Ujjani, Chaitra S.
    Eyre, Toby A.
    Zinzani, Pier Luigi
    Alencar, Alvaro J.
    Gastinne, Thomas
    Ghia, Paolo
    Lamanna, Nicole
    Hoffmann, Marc S.
    Patel, Manish R.
    Flinn, Ian
    Gerson, James N.
    Ma, Shuo
    Coombs, Catherine C.
    Cheah, Chan Y.
    Lech-Maranda, Ewa
    Fakhri, Bita
    Kim, Won Seog
    Barve, Minal A.
    Cohen, Jonathon B.
    Jurczak, Wojciech
    Thompson, Meghan C.
    Roeker, Lindsey E.
    Bao, Katherine
    Cangemi, Nicholas A.
    Kherani, Jennifer F.
    Walgren, Richard A.
    Han, Hongmei
    Ruppert, Amy S.
    Mato, Anthony R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 13 - 13
  • [36] Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies (vol 28, pg 309, 2023)
    Munoz, Javier
    Sarosiek, Shayna
    Castillo, Jorge J.
    ONCOLOGIST, 2023, 28 (06): : E487 - E487
  • [37] Inhibitors of B-Cell Receptor Signaling for Patients With B-Cell Malignancies
    Choi, Michael Y.
    Kipps, Thomas J.
    CANCER JOURNAL, 2012, 18 (05): : 404 - 410
  • [38] Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study
    Shadman, Mazyar
    Flinn, Ian W.
    Levy, Moshe Y.
    Porter, Ryan F.
    Burke, John M.
    Zafar, Syed F.
    Misleh, Jamal
    Kingsley, Edwin C.
    Yimer, Habte A.
    Freeman, Benjamin
    Rao, Subramanya S.
    Chaudhry, Arvind
    Tumula, Praveen K.
    Gandhi, Mitul D.
    Manda, Sudhir
    Chen, Dih-Yih
    By, Kunthel
    Xu, Linlin
    Liu, Ye
    Crescenzo, Rocco
    Idoine, Adam
    Zhang, Xiaoping
    Cohen, Aileen
    Huang, Jane
    Sharman, Jeff P.
    LANCET HAEMATOLOGY, 2023, 10 (01): : E35 - E45
  • [39] SPECIFIC INHIBITION OF BTK IS EFFECTIVE IN B-CELL MALIGNANCIES
    不详
    CANCER DISCOVERY, 2012, 2 (12) : 1073 - 1073
  • [40] Pooled safety analysis of zanubrutinib monotherapy in Asian patients with B cell malignancies
    Zhu, J.
    Li, J.
    Tam, C. S.
    Guo, H.
    Wang, L.
    Zhou, H.
    Zhang, M.
    Zhang, J.
    Cohen, A.
    Bahadur, N.
    Khanna, P.
    Kim, W. S.
    Qiu, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1599 - S1600
12345